Insilico Medicine Company
Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases. It pioneered the applications of the generative adversarial networks (GANs), reinforcement learning, transfer learning, and meta-learning for the generation of novel molecular structures for the diseases with known and unknown targets, and, unlike the other companies in the field, is developing the end-to-end pipeline covering every step of drug discovery, clinical trials analysis, and digital medicine. Insilico Medicine is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with Life Extension, the company launched a range of nutraceutical products, which were compounded using advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
Investors
.png)
.png)
.png)
.jpeg)
(Reupload).png)
(Reupload).png)
.png)
.png)
.png)
(Reupload).png)
.png)
(Reupload).png)
.png)
.png)
.png)
.png)
.png)
Technology:
Artificial Intelligence, Biotechnology, Genetics, Health Care, Pharmaceutical
Industry:
End-to-end Drug Development
Headquarters:
Hong Kong, Hong Kong Island, Hong Kong
Founded Date:
2014-01-01
Employees Number:
11-50
Funding Status:
Late Stage Venture
Investors Number:
27
Total Funding:
306300000
Estimated Revenue:
Less than $1M
Last Funding Date:
2022-01-11
Last Funding Type:
Venture - Series Unknown
Register and Claim Ownership